Haemonetics
329 hedge funds and large institutions have $3.71B invested in Haemonetics in 2026 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 108 increasing their positions, 121 reducing their positions, and 46 closing their positions.
199% more call options, than puts
Call options by funds: $29M | Put options by funds: $9.69M
39% more capital invested
Capital invested by funds: $2.68B → $3.71B (+$1.03B)
20% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 46
6.71% more ownership
Funds ownership: 102.48% → 109.18% (+6.7%)
2% more funds holding
Funds holding: 324 → 329 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 121
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$132M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$80.4M |
| 3 |
Neuberger Berman Group
New York
|
+$39.7M |
| 4 |
Millennium Management
New York
|
+$36M |
| 5 |
Holocene Advisors
New York
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$70M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$63.5M |
| 3 |
NPCM
North Peak Capital Management
New York
|
-$42.1M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$28.8M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$24.7M |
HAE Hedge Fund Activity: Q2 2026 in Review
329 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2026, worth a combined $3.71B — up 39% from $2.68B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new HAE positions and 46 closed out — a net gain of 9 holders — while 108 added to existing stakes and 121 trimmed.
The largest buyer was Ariel Investments, opening a new position worth an estimated $132M. The largest seller was AQR Capital Management, cutting an estimated $70M.
- 329 institutional investors held Haemonetics (HAE) as of Q2 2026, up from 324 in Q1 2026.
- Funds reported $3.71B of Haemonetics stock for Q2 2026, up 39% quarter-over-quarter.
- 55 funds opened new Haemonetics positions in Q2 2026 and 46 closed out, a net change of +9 holders.
- The largest Haemonetics buyer in Q2 2026 was Ariel Investments, an estimated $132M added.
- The largest Haemonetics seller in Q2 2026 was AQR Capital Management, an estimated $70M sold.
Based on aggregated 13F filings for Q2 2026.